Gobello Cristina, Castex Gervasio, Klima Liliana, Rodríguez Raúl, Corrada Yanina
Small Animal Clinic, Faculty of Veterinary Medicine, National University of La Plata, CC 296, La Plata B1900 AVVW, Argentina.
Theriogenology. 2003 Sep 15;60(5):901-8. doi: 10.1016/s0093-691x(03)00094-3.
To compare the efficacy and safety of two protocols using a combination of aglepristone and cloprostenol for the treatment of open cervix pyometra in the bitch and to describe the progesterone (P4) serum profiles before and during treatments, 15 bitches were randomly allocated into two treatment groups: I (n = 8): aglepristone was administered at 10mg/kg, s.c., on Days 1, 3, 8, and 15 (if not cured), combined with cloprostenol at the dose of 1 microg/kg, s.c., on Days 3 and 8, and II (n = 7): received the same treatment with aglepristone as Treatment I but cloprostenol on Days 3, 5, 8 10, 12, and 15 (if not cured). Before the beginning of the treatments and then on Days 8, 15, and 29 all bitches were evaluated for clinical signs, side effects, hemogram, serum P4 concentrations, and uterus diameters. Bitches in both treatment groups, with (n = 6) or without (n = 9; > or =1.2 ng/ml) initial basal P4 serum concentrations, achieved treatment success without side effects and no significant differences, either on Day 15 (6/8 for Treatment I and 4/7 for Treatment II) or on Day 29 (2/8 for Treatment I and 3/7 for Treatment II). In both treatments groups, clinical signs, blood parameters, and uterine diameters improved to normal values throughout the experiments. A significant interaction between day and treatment was found for percentage change in P4 when all bitches were considered together. Redevelopment of pyometra in the next estrous cycle occurred in 20% of the bitches. One nonrecurrent bitch was mated and whelped a normal litter. It is concluded that these two combined protocols proved to be efficient and safe in reversing clinical signs of open cervix pyometra independently of initial P4 concentrations and that the number of cloprostenol administrations seemed to have an effect on P4 serum changes throughout treatments.
为比较两种使用阿孕瑞司酮和氯前列醇联合治疗母犬开放性子宫蓄脓的方案的疗效和安全性,并描述治疗前及治疗期间的血清孕酮(P4)水平,将15只母犬随机分为两个治疗组:I组(n = 8):在第1、3、8天及15天(若未治愈)皮下注射阿孕瑞司酮,剂量为10mg/kg,并在第3天和第8天皮下注射剂量为1μg/kg的氯前列醇;II组(n = 7):接受与I组相同的阿孕瑞司酮治疗,但氯前列醇在第3、5、8、10、12天及15天(若未治愈)注射。在治疗开始前以及随后的第8、15和29天,对所有母犬进行临床症状、副作用、血常规、血清P4浓度和子宫直径评估。两个治疗组中,初始基础血清P4浓度有(n = 6)或无(n = 9;≥1.2 ng/ml)的母犬均成功治愈,且无副作用,在第15天(I组6/8,II组4/7)或第29天(I组2/8,II组3/7)均无显著差异。在两个治疗组中,整个实验过程中临床症状、血液参数和子宫直径均恢复至正常水平。当将所有母犬一起考虑时,发现P4百分比变化在天数和治疗之间存在显著交互作用。20%的母犬在下一个发情周期中子宫蓄脓复发。一只未复发的母犬交配并产下正常一窝幼犬。结论是,这两种联合方案在逆转开放性子宫蓄脓的临床症状方面被证明是有效且安全的,与初始P4浓度无关,且氯前列醇的给药次数似乎对整个治疗过程中的血清P4变化有影响。